An established, chemical technology innovator, on a mission to accelerate the discovery and development of high-quality drugs
The company started in 2014, based on the discoveries made in the Xiao group at the University of Liverpool, about the enantioselective reduction of pyridines to the corresponding chiral piperdines.
The Xiao group rapidly realised the potential of these researches, as many marketed drugs contain substituted piperidine rings. These initial discoveries led to the formation of LCC.
Since then, we’ve enhanced the scope of our expertise to provide leading scientific organisations around the world with access to chirally-pure compounds that play their part in small molecule drug discovery.
Our chemical technologies enable access to unique, 3D-rich, chiral building blocks, that were previously scarce.
We have moved to new labs in Runcorn to facilitate the combination of our production facilities with our R&D and PSL teams.
The move also allows LCC to keep expanding our team and capabilities as we continue to accelerate your discovery.Contact us
Our initial success was based on the catalytic enantioselective reduction of pyridines, however we have continued to enhance the scope of our expertise, to provide a broad range of chiral (N-)heterocycles.
Our experience allows us to utilise various approaches including asymmetric hydrogenation reactions, catalytic cross-couplings, and cyclisation chemistries. Our highly skilled R&D team can support your projects to give access to innovative new therapies.
Every member of LCC (past and present), have contributed in shaping LCC into who we are today. The combination of skillsets, along with excellent team-spirit, focus, and forward-thinking have allowed LCC to innovate within our field. The LCC Team continue to achieve our goal in supporting our customers to expedite drug discovery.
CEO & Founder
Head of Product Design
Head of PSL
Head of Finance & Company Secretary
Head of Business Development